FDA-cleared profile

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Clinical role
Post-processing and semi-automated plaque and stenosis assessment to provide qualitative and quantitative information for physician review.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult cardiac CT images acquired from a CT scanner in DICOM format for CCTA evaluation of CAD or suspected CAD.
  • Who uses it?Intended users: Qualified medical professionals experienced in examining cardiovascular CT images as part of comprehensive diagnostic decision-making.
  • What does the software produce?Output: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
  • What is its most important limitation?Key limitation: The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.

Clinical takeaway. Clinical role: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Evidence takeaway. Evidence from the reviewed source record: K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Post-processing and semi-automated plaque and stenosis assessment to provide qualitative and quantitative information for physician review.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult cardiac CT images acquired from a CT scanner in DICOM format for CCTA evaluation of CAD or suspected CAD.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult cardiac CT/CCTA interpretation in cardiology or radiology practice.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified medical professionals experienced in examining cardiovascular CT images as part of comprehensive diagnostic decision-making.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is an adjunct to comprehensive physician interpretation, is limited to cardiac CT from a CT scanner, and its semi-automated algorithms are intended for adults. The public K251027 packet does not establish clinical outcomes or product-wide diagnostic accuracy beyond the reported regulatory endpoints.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K251027 FDA evidence is a regulatory ML segmentation and plaque-volume validation package; no independent publication or trial was promoted in this review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Lumen mean DSC

0.76 Dice similarity coefficient

  • EndpointMean lumen segmentation overlap against three-expert reference
  • PopulationValidation images from multiple U.S. sites and major CT vendors; public summary does not state a case count
  • Tested versioncvi42 Coronary Plaque Module in K251027

Wall mean DSC

0.8 Dice similarity coefficient

  • EndpointMean vessel-wall segmentation overlap against three-expert reference
  • PopulationValidation images from multiple U.S. sites and major CT vendors
  • Tested versioncvi42 Coronary Plaque Module in K251027

Low-attenuation plaque volume PCC

0.74 Pearson correlation coefficient

  • EndpointCorrelation of derived low-attenuation plaque volume with reference
  • PopulationValidation images from multiple U.S. sites and major CT vendors
  • Tested versioncvi42 Coronary Plaque Module in K251027

K251027 machine-learning validation of the Coronary Plaque Module

  • DesignRetrospective regulatory validation against reference standards established by three expert annotators; development and validation images were separated.
  • PopulationAdult cardiac CT/CCTA images from multiple U.S. sources and major CT vendors
  • Scopeexact submission
  • Tested versioncvi42 Coronary Plaque Software Application configuration described in K251027
  • IndependenceSponsor or vendor study

K251027

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251027. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
  • Product family
  • Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251027 or establish individual claim eligibility.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult cardiac CT images acquired from a CT scanner in DICOM format for CCTA evaluation of CAD or suspected CAD.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

  2. Routing

    Source context, not route validation: The FDA packet describes DICOM-compliant CT import and display, cardiac CT post-processing, and reporting; compatibility with a specific PACS, RIS, EHR, interface engine, and local routing configuration requires acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

  3. AI processing

    Source context, not route validation: The exact FDA package describes the Coronary Plaque Module running on macOS or Microsoft Windows computer operating systems and able to be integrated into image viewing software such as Circle's cvi42 Software Application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Computer operating system macOS, Microsoft Windows" … "The Coronary Plaque Module can be integrated into an image viewing software intended for visualization of cardiac images, such as Circle’s FDA-cleared cvi42 Software Application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

  4. Returned objects

    Source context, not route validation: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

  5. Viewer/worklist/report

    Unresolved route: Calcified, non-calcified, low-attenuation, and total plaque volumes and burdens; remodeling index; diameter- and area-based stenosis; lesion length; on-screen results and a Coronaries Plaque Module report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the Coronary Plaque Module running on macOS or Microsoft Windows computer operating systems and able to be integrated into image viewing software such as Circle's cvi42 Software Application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Computer operating system macOS, Microsoft Windows" … "The Coronary Plaque Module can be integrated into an image viewing software intended for visualization of cardiac images, such as Circle’s FDA-cleared cvi42 Software Application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The FDA packet describes DICOM-compliant CT import and display, cardiac CT post-processing, and reporting; compatibility with a specific PACS, RIS, EHR, interface engine, and local routing configuration requires acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Circle describes the current cvi42 Plaque family as on-premise and says data need not be sent to an outside reading service; the official page is not a scoped security attestation for the K251027 release.
  • Product family
  • Checked 2026-09-07

Confirm deployed version, network boundaries, identity, encryption, audit, retention, vulnerability management, and incident response.

Training
Use is limited to qualified medical professionals experienced in cardiovascular CT; local training and competency for plaque editing, report review, and failure handling remain site responsibilities.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor eligible CCTA inputs, segmentation and plaque edits, report completeness, failed or repeated analyses, PACS/RIS delivery, reader overrides, subgroup performance, downtime, updates, complaints, and recalls by exact K251027 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA input, output, and validation scope.

DICOM cardiac CT workflow

The exact submission imports and displays DICOM cardiac CT and provides semi-automated plaque and vessel analysis with manual review controls.

exact submission · checked 2026-09-07

On-premise family workflow

Circle describes current cvi42 Plaque as on-premise, AI-enabled plaque quantification integrated into the CT workflow without sending data to an outside reading service.

product family · checked 2026-09-07

Current family capability; verify whether the installed K251027 release, licensing, and local integration match this description.

Regulatory identity cross-check

Circle's regulatory page lists cvi42 FDA 510(k) K251027; the page does not establish every current family feature for that exact cleared configuration.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251027
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-10-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor regulatory page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K251027 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

11 sources - 3 history items

Source ledger

  1. FDA 510(k) K251027: cvi42 Coronary Plaque Software Application

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, evidenceMetrics, evidenceStudies, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. cvi42 Coronary Plaque Software Application model card (K251027)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. cvi42 | Plaque official product page

    Circle Cardiovascular Imaging - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, implementationCapabilities, security

  8. Circle CVI U.S. regulatory clearances

    Circle Cardiovascular Imaging - Accessed 2026-09-07

    Scope: identity, productFamily, currentCommercialContext

  9. openFDA exact recall query for K251027

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  10. CMS LCD L39913 version 7

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

  11. CMS Article A59813 version 6

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

Research history

  1. K251027 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243229

Bunkerhill AVC

BunkerHill Health

Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-01-27
FDA-cleared K183012

vascuCAP

Elucid Bioimaging Inc.

Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2018-12-21
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history